Information Provided By: 
Fly News Breaks for June 7, 2017
JAZZ
Jun 7, 2017 | 08:23 EDT
Cowen analyst Ken Cacciatore noted Jazz Pharmaceuticals presented positive Phase lll data on its drug candidate to treat daytime sleepiness and said the results were as good as could be hoped for. Given its efficacy/safety profile, he believes JZP-110 is "best-in-class" and likely a $750M product and recommends investors get involved now. Cacciatore reiterated his Outperform rating and $190 price target on Jazz Pharmaceuticals shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
